Corrigendum to Notice of 32nd Annual General Meeting

Orchid Pharma has issued a corrigendum to its 32nd AGM notice (scheduled for September 20, 2025) to correct Item No. 8, which seeks shareholder approval to modify the use of proceeds from its Rs. 400 crore QIP completed in June 2023. The revised allocation increases funding for subsidiary Orchid Bio Pharma's Jammu manufacturing facility from Rs. 90 Cr to Rs. 135 Cr, slashes the new API block allocation at Alathur from Rs. 99.82 Cr to just Rs. 0.36 Cr, and boosts debt repayment allocation from Rs. 141 Cr to Rs. 195.46 Cr. As of June 30, 2025, Rs. 275.15 Cr has been utilised and Rs. 124.85 Cr remains unutilised. The company cites that over 70% of the Jammu project funds are already deployed, the API block project is being pushed to a later stage, and the current mismatch between FD-held cash and 7.50%-8.80% working capital borrowings is hurting profitability by 1.5%-2.0%. The AGM also covers routine items including adoption of FY25 financial statements, reappointment of a director by rotation, ratification of cost auditor, appointment of secretarial auditor, re-appointment of three independent directors, and approval of related party transactions with Otsuka Chemicals (India) up to Rs. 400 Cr.